BI Asset Management Fondsmaeglerselskab A S Buys 132,795 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

BI Asset Management Fondsmaeglerselskab A S boosted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 45.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 427,207 shares of the biopharmaceutical company’s stock after acquiring an additional 132,795 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S owned 0.34% of Halozyme Therapeutics worth $20,425,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Stifel Financial Corp lifted its holdings in Halozyme Therapeutics by 126.3% during the 3rd quarter. Stifel Financial Corp now owns 17,121 shares of the biopharmaceutical company’s stock valued at $980,000 after purchasing an additional 9,555 shares during the last quarter. MML Investors Services LLC increased its holdings in shares of Halozyme Therapeutics by 80.7% during the third quarter. MML Investors Services LLC now owns 9,779 shares of the biopharmaceutical company’s stock worth $560,000 after buying an additional 4,366 shares in the last quarter. M&T Bank Corp raised its stake in shares of Halozyme Therapeutics by 0.5% in the third quarter. M&T Bank Corp now owns 111,239 shares of the biopharmaceutical company’s stock valued at $6,367,000 after acquiring an additional 561 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $434,000. Finally, World Investment Advisors LLC bought a new stake in Halozyme Therapeutics during the 3rd quarter worth approximately $3,293,000. 97.79% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the transaction, the director now owns 33,611 shares in the company, valued at $1,972,629.59. The trade was a 12.95 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the transaction, the senior vice president now owns 185,453 shares of the company’s stock, valued at $10,765,546.65. This represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,200 shares of company stock valued at $1,286,568 in the last 90 days. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Price Performance

Shares of HALO stock opened at $58.79 on Friday. The firm’s 50 day moving average price is $60.45 and its two-hundred day moving average price is $55.02. The stock has a market cap of $7.26 billion, a PE ratio of 17.14, a PEG ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 52-week low of $37.97 and a 52-week high of $66.00. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. As a group, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on HALO shares. Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Benchmark restated a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Finally, Piper Sandler increased their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.